ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1277

Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms

Amanda Eudy1, Jennifer Rogers2, Amy Corneli2, Kevin McKenna2, David Pisetsky3, Mithu Maheswaranathan2, Lisa Criscione-Schreiber2, Jayanth Doss1, Rebecca Sadun1, Kai Sun2 and Megan Clowse4, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University Medical Center, Durham, NC, 4Duke University, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The Type 1 & 2 SLE Model was developed to better characterize the signs and symptoms of SLE. Type 1 SLE consists of inflammatory manifestations like arthritis, nephritis, and rashes; Type 2 SLE includes symptoms of fatigue, myalgia, mood disturbance, and cognitive dysfunction. In this study, we explored patient experiences living with Type 2 SLE symptoms.

Methods: Semi-structured in-depth interviews were conducted among adult participants meeting ACR or SLICC criteria for SLE. Participants were purposefully selected for age, race, sex, and nephritis history. All interviews were audio-recorded and transcribed. Data were analyzed through episode profile analysis. Two rheumatologists and a lupus researcher independently read transcripts, summarized patterns of Type 1 & 2 SLE symptoms described by participants, and identified broader themes about the relationship between Type 1 & 2 SLE symptoms. Through this process, two patterns of Type 2 SLE symptoms were identified. The two patterns were then descriptively compared.

Results: We interviewed 42 patients with SLE (93% female, 52% Black, mean age 45 years, mean disease duration 15 years). All but two participants reported experiencing Type 2 SLE symptoms at some point during their disease course.

Type 2 SLE Pattern: Two patterns of Type 2 SLE were identified: intermittent or resolving (n=18) and persistent or pervasive (n=24). Patients with intermittent Type 2 often experience Type 2 symptoms in tandem with or as a result of Type 1 symptoms. In these patients, Type 2 symptoms improve and are often not present when Type 1 disease is inactive, leaving these patients feeling generally well. In contrast, patients with persistent Type 2 experience Type 2 symptoms regardless of Type 1 symptoms. For these patients, Type 2 symptoms are always present, although the severity may fluctuate.

Demographics: Compared to patients with persistent Type 2, patients with intermittent Type 2 were typically younger (39 vs. 50 years old) and more often Black (67% vs. 42%).

Self-Reported Symptoms during Disease Course: A majority of participants in both groups reported they had experienced brain fog and depression, and all but two participants reported experiencing fatigue. Almost all had experienced traditional lupus symptoms of joint pain, hair loss, and rash. Participants in the persistent Type 2 group were more likely to describe experiencing anxiety, muscle pain, and widespread pain.

Clinical Criteria: Almost all participants met musculoskeletal and mucocutaneous SLE criteria. However, more patients with intermittent Type 2 met renal, hematologic, and immunologic criteria.

Conclusion: Almost all patients in our study experienced Type 2 symptoms, and we found two unique patterns of Type 2 SLE: intermittent and persistent. Patients with intermittent Type 2 SLE have more internal SLE manifestations and feel generally well when Type 1 is inactive. Patients with persistent Type 2 always experience Type 2 symptoms despite inactive Type 1. We hypothesize some degree of Type 2 symptoms in each group might be inflammation-driven; however, the persistence of Type 2 in one group suggests different underlying pathophysiology.


Disclosures: A. Eudy, NIH NCATS Award Number 1KL2TR002554, 5, Pfizer, 5, Exagen, 5; J. Rogers, Exagen, Inc, 5; A. Corneli, None; K. McKenna, None; D. Pisetsky, Immunovant, 2; M. Maheswaranathan, None; L. Criscione-Schreiber, None; J. Doss, Pfizer, 5; R. Sadun, None; K. Sun, None; M. Clowse, UCB Pharma, 2, Pfizer, 5, GSK, 2, 5.

To cite this abstract in AMA style:

Eudy A, Rogers J, Corneli A, McKenna K, Pisetsky D, Maheswaranathan M, Criscione-Schreiber L, Doss J, Sadun R, Sun K, Clowse M. Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/patient-perspectives-on-two-distinct-patterns-of-type-2-sle-symptoms/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perspectives-on-two-distinct-patterns-of-type-2-sle-symptoms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology